Yeah they boo and hiss here - then the crazies come over to my site financialchat.com and bombard me with mate messages that hurt my feelings.
Technically MANY of the mid cap biotechs look horrible - MNTA isnt alone but I am noticing that many in the $600m - $5b market cap area are lookign very ugly.
AMAG - we just covered yesterday off the 200dma but take a look at the underperformance of nearly all names in that area of the market cap curve.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.